Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...

Until this month, Radio Free Asia had successfully resisted Trump officials who had tried to render it obsolete. By Minho Kim Senate Republicans cited a call by the American Federation of Government ...

The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States.